Dasatinib-Induced Nephrotic Syndrome: A Case Report

Ahmed ElShaer 1, Mazen Almasry 1, Maher Alawar 2, Hassan Masoud 3, Abdul Rahman El Kinge 4

1. Internal Medicine, Alfaisal University College of Medicine, Riyadh, SAU 2. Nephrology, Specialized Medical Center, Riyadh, SAU 3. Pathology, Specialized Medical Center, Riyadh, SAU 4. Hematology and Medical Oncology, NMC Royal Hospital, Sharjah, ARE

Abstract
Second-generation tyrosine kinase inhibitors (TKI), such as nilotinib and dasatinib, are used in the first-line treatment of chronic myeloid leukemia (CML), usually after the failure or resistance to imatinib. Despite a good safety profile, medications in this category have an increased incidence of specific adverse events such as pulmonary hypertension, pleural effusion, and cardiovascular/peripheral arterial events. However, renal complications are rarely reported and observed. We herein report a case of a 46-year-old patient with CML who developed nephrotic syndrome upon switching from imatinib to dasatinib therapy, with the resolution of symptoms upon treatment discontinuation and switching to nilotinib. Limited cases were reported in the literature. It is thought that the inhibition of the vascular endothelial growth factor (VEGF) pathway is the main mechanism leading to proteinuria. Dasatinib-induced nephrotic syndrome should be looked for as it can be resolved by either reducing the dose or stopping it altogether and switching to another TKI.

Introduction
Chronic myelogenous leukemia (CML) is a hematological malignancy that accounts for almost 20% of leukemia cases in adults [1]. CML is characterized by a reciprocal t(9,22) translocation resulting in the fusion of BCR-ABL. This genetic abnormality, which continuously activates tyrosine kinase (TK) resulting in leukemia–cell proliferation, is the major mechanism behind the development of the disease [2]. The discovery of t(9,22) translocation pathogenesis led to a revolution in the treatment of CML as it paved the way to the development and approval of tyrosine kinase inhibitors (TKIs). Imatinib is a first-generation tyrosine kinase inhibitor (TKI) used in the treatment of chronic myeloid leukemia (CML) [3]. Although imatinib has a good safety profile, 30% of patients develop primary or secondary resistance, which led to the development of second-generation TKIs, namely dasatinib and nilotinib [4-7]. Several side-effects of special interest were reported with second-generation TKIs including pulmonary hypertension, pleural effusion, and cardiovascular/peripheral arterial events [8, 9]. However, renal complications are less commonly reported and observed. We herein report a case of a 46-year-old patient with chronic myelogenous leukemia who developed nephrotic syndrome upon switching from imatinib to dasatinib therapy, showing a resolution of symptoms upon treatment discontinuation, and switching to nilotinib. Similar cases in the literature are reviewed with inhibition of the vascular endothelial growth factor (VEGF) pathway thought to be the main mechanism leading to proteinuria. Dasatinib-induced nephrotic syndrome can be resolved by either reducing the dose or stopping dasatinib and switching to another TKI.

Case Presentation
A 46-year-old female patient was diagnosed with Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia (Ph+ CML) in 2004, and she was maintained on imatinib mesylate 400 mg daily. In 2011, she had a loss of molecular and cytogenetic remission on imatinib. Accordingly, her treatment was switched to dasatinib 100 mg daily which she could not tolerate due to severe diffuse bone pain. The dose was reduced until the bone pain disappeared and she was maintained on 50 mg daily. After a year of therapy, she achieved major molecular response with undetectable BCR-ABL levels. However, five years later, while still in major molecular response, she presented with peculiar complaints. She had progressive periportal puffiness, abdominal fullness, and shortness of breath on exertion. Physical examination revealed bilateral lower limb pitting edema +2, bilateral decreased air entry mainly on the left side, and hepatomegaly. Urinalysis showed 3+ proteinuria with epithelial cells. The spot urine protein to creatinine ratio was 5.33 mg/dL which indicated nephrotic-range proteinuria without hematuria and with a normal creatinine of 0.79 mg/dL. Her 24-hour-urinary-protein test was collected and found to be 5.9 g/dL. In addition, the patient underwent serological testing of antinuclear antibody, anti-double-stranded DNA antibodies, and viral hepatitis which were all negative. Thereafter, the patient was evaluated by a nephrologist. A kidney biopsy was performed to reach a diagnosis. The findings of the biopsy on light microscopy showed normal cellularity with patent peripheral capillaries. However, there was segmental duplication in some glomeruli and few glomeruli had hyaline-type subendothelial and intramembranous deposits. The tubules showed...
mild acute injury with luminal ectasia and epithelial simplification. Tubular cells contained intracytoplasmic protein resorption droplets. The interstitium had no signs of pathology. The arteries and arterioles were normal with no acute thrombi. Electron microscopy showed endothelial cells segmentally swollen with loss of fenestrations with moderate effacement of the foot processes on the podocyte (Figure 1A). Accumulation of lipid droplets within the subendothelial zone was also noted (Figure 1B). The immunofluorescence study revealed no positive results for anti-IgA, IgG, IgM, C1q, C3, albumin, fibrinogen, kappa, and lambda. One month after discontinuing dasatinib, urinalysis showed 1+ proteinuria, spot urine protein to creatinine ratio decreased to 0.61 mg/g and total urine protein decreased to 822 mg/L. At the two-month follow-up, urinalysis showed 1+ proteinuria, urine protein to creatinine ratio further decreased to 0.31 mg/g and the total urine protein was 436 mg/L. The patient was switched to nilotinib 200 mg twice daily where she remained in major molecular response to date.

FIGURE 1: (A) Podocytes display moderate foot process effacement involving approximately 50% of the total peripheral capillary surface area. (B) Arrow pointing at the accumulation of lipid droplets within the subendothelial zone.

Discussion

Nephrotic syndrome is a renal disease that occurs due to damage to the podocytes leading to a disruption in the glomerular filtration membrane. This results in hypercholesterolemia and proteinuria causing peripheral edema. Nephrotic syndrome is primarily caused by diseases of the glomerulus or as a secondary effect to a systematic disease [10].

Dasatinib, a second-generation TKI, is used to treat Ph+ CML and acute lymphoblastic leukemia (ALL), in addition to a spectrum of solid tumors that display c-Kit [11]. Although this drug is metabolized through the liver, nephrotic syndrome has been reported as a potential side effect in rare cases [12]. In phase 1 clinical trial that focused on dose-escalation and pharmacokinetics of dasatinib as a treatment for advanced solid tumors, 18% of participants developed proteinuria [13]. This adverse event is unrecognized as a potentially serious one and is possibly ignored. To the best of our knowledge, eight case reports of dasatinib-induced nephrotic syndrome were reported in the literature in patients with CML [10, 11, 14-19], making this present case, to our knowledge, the ninth case. In all CML cases, the major molecular response was maintained after either switching to another TKI or reducing the dose of dasatinib. Some proposed that reducing the dose by half was enough to resolve the proteinuria [19]. This indicates that the severity of proteinuria may be dose-dependent. The main clinical data of our case together with those in the literature are illustrated in Table 1.
TABLE 1: Reported cases of Dasatinib-induced nephrotic syndrome

| Case | Ref | Patient | Duration of dasatinib | Urinary protein excretion | Creatinine (mg/dl) | BCR-ABL ratio at dasatinib discontinuation | Duration to resolution | BCR-ABL ratio at last follow-up | Renal biopsy | Treatment | Prognosis |
|------|-----|---------|----------------------|--------------------------|-------------------|------------------------------------------|----------------------|--------------------------------|-------------|-----------|-----------|
| 1    | De Luca et al. [10] | 45, F | 6 months | 4.0 g/day | 0.9 | 2.67 | 2 weeks | 0.036 | NA | Switch to imatinib | Remission |
| 2    | Ruebner et al. [11] | 3, F | 17 months | UR/Ucr = 17 g/gCr | 0.3 | NA | 2 months | Negative | Focal foot process effacement | Discontinue | Remission |
| 3    | Wallace et al. [14] | 63, F | 3 months | 3.9 g/day | 0.79 | NA | 2 weeks | Negative | Focal foot process effacement | Switch to imatinib | Remission |
| 4    | Ochiai et al. [15] | 40, M | 3 months | 5.7 g/day | 0.87 | NA | 2 weeks | NA | Endothelial cell injury and foot process effacement | Switch to nilotinib | Remission |
| 5    | Koinuma et al. [16] | 52, F | 5 years | UR/Ucr=2.18 g/gCr | 0.83 | NA | 3 weeks | NA | Diffuse foot process effacement over the entire capillary surface | Switch to bosutinib | Remission |
| 6    | Piscitani et al. [17] | 43, F | 17 months | 7.03 g/day | 0.9 | NA | 5 months | NA | Focal podocyte foot process effacement, and segmental endothelial cell swelling with a slight expansion of the subendothelial space | None | Unknown |
| 7    | Stanchina et al. [18] | 53, M | < 10 days | 10 g/day | NA | NA | 3 days | NA | NA | Switch to imatinib | unknown |
| 8    | Mendez et al. [19] | 33, F | 2 years | NA | NA | NA | NA | NA | NA | Dose reduction | Remission |
| 9    | Our case | 46, F | 5 years | UR/Ucr=5.33 g/gCr | 0.80 | 0.02% | 1 week | 0.004% | Endothelial cells segmentally swollen with loss of fenestrations with moderate effacement of the foot processes on the podocyte | Switch to nilotinib | Remission |

The safety profile of different TKIs varies according to the specific pathway of inhibition. For instance, blocking TKs such as c-abl, platelet-derived growth factor receptor, and epidermal growth factor receptor have shown beneficial outcomes on diseased kidneys in murine models [14]. On the other hand, the blockage of TKs in signaling pathways involving vascular endothelial growth factor (VEGF) can be damaging to the kidney, and hence, affecting its function [20]. The exact mechanism behind dasatinib-induced proteinuria remains obscure. The most acceptable theory suggests that blocking VEGF is the main mechanism behind dasatinib-induced proteinuria. VEGFs are known to play a central role in podocyte cytoskeletal organization [21]. The importance of VEGF in the development and function of glomerular endothelium was established by knocking out the VEGF gene from podocytes in a mouse model. As a result, this led to the development of proteinuria and hypertension in all mice [20]. Dasatinib inhibits Src family kinases which regulate the VEGF pathway in podocytes. Hence, it might induce proteinuria as seen in our case [21-24]. In contrast, nilotinib is thought to be renal protective and can prolong survival in patients with chronic kidney disease [25].

Conclusions
In summary, nephrotic syndrome is a rare side effect that can be seen in patients treated with dasatinib. Inhibiting the VEGF pathway by dasatinib is thought to be the main mechanism leading to proteinuria. Dasatinib-induced nephrotic syndrome can be resolved by either reducing the dose or stopping dasatinib and switching to another TKI.

Additional Information
Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Acknowledgements

Ahmed El Shaer and Mazen Almasry are both the primary authors of this article.

References

1. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzil A, Jemal A: Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017, 67:177-95. 10.3322/caac.21395
2. Goldman JM, Melo JV: Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001, 344:1084-6. 10.1056/NEJM200104053441409
3. Drucker BJ, Guilhot F, O’Brien SG, et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006, 355:2408-17. 10.1056/NEJMoa062867
4. Branford S, Rudzki Z, Walsh S, et al.: Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003, 102:276-83. 10.1182/blood-2002-09-2896
5. Kujawski L, Talpar M: Strategies for overcoming imatinib resistance in chronic myeloid leukemia. Leuk Lymphoma. 2007, 48:2510-22. 10.1080/10428190701665988
6. Larson RA, Hochhaus A, Hughes TP, et al.: Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012, 26:2197-203. 10.1038/leu.2012.134
7. Kantarjian HM, Shah NP, Cortes JE, et al.: Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 5 trial (DASISION). Blood. 2012, 119:1123-9. 10.1182/blood-2011-08-76087
8. Abruzzese E, Brecchia M, Latagliata R: Second-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukaemia (CML). BiolDrugs. 2014, 28:17-26. 10.1007/s40259-013-0056-z
9. Jabbour E, Kantarjian H, Cortes J: Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk. 2015, 15:523-34. 10.1016/j.clml.2015.03.006
10. De Luca M, Carmesino I, Stefanizzi G, et al.: Nephrotic proteinuria developed under dasatinib treatment in a patient with chronic myeloid leukemia: a case report and review of the literature. Anticancer Res. 2016, 5:1106.
11. Ruebner RL, Copelowitch L, Evageliou NF, Denburg MR, Belasco JB, Kaplan BS: Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature. Pediatr Nephrol. 2014, 29:863-9. 10.1007/s00467-013-2696-0
12. Li X, He Y, Ruiz GH, Koenig M, Cameron MD, Vojkovdy T: Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways. Drug Metab Dispos. 2009, 37:1424-50. 10.1124/dmd.108.025952
13. Demetri GD, Lo Russo P, MacPherson IR, et al.: Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res. 2009, 15:6532-40. 10.1158/1078-0432.CCR-09-0224
14. Wallace E, Lydon W, Chunmey P, James EA, Fatima H: Dasatinib-induced nephrotic-range proteinuria. Am J Kidney Dis. 2015, 61:1026-31. 10.1053/j.ajkd.2013.01.022
15. Ochiai S, Sato Y, Minakawa A, Fukuda A, Fujimoto S: Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenenous leukemia: a case report. BMC Nephrol. 2019, 20:87. 10.1186/s12882-019-1273-6
16. Koinuma K, Sakairi T, Watanabe Y, et al.: A case of long-term dasatinib-induced proteinuria and glomerular injury. CEN Case Rep. 2020, 9:539-64. 10.1007/s13755-020-00484-8
17. Fiscitani L, Sirrolli V, Di Liberato L, Morrone M, Bonon mini M: Nephrotoxicity associated with novel anticancer agents (aflibercept, dasatinib, nivolumab): case series and nephrological considerations. Int J Mol Sci. 2020, 21: 4878. 10.3390/ijms21144878
18. Stanchina M, McKinnell Z, Park JH, Stein EM, Cai SF, Taylor J: BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon. Leuk Res Rep. 2020, 10:100211. 10.1016/j.lrr.2020.100211
19. Mandac-Rogulj I, Matrić I, Arsov B, Bohan L, Jugić-Novak A, Mihalic B, Primorac D: Dasatinib-induced nephrotic syndrome: a case of phenocconversion. Croat Med J. 2019, 60:250-4. 10.3325/cmj.2019.60.250
20. Eremina V, Jefferson A, Kowalewska J, et al.: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008, 558:1129-36. 10.1056/NEJMoA0707330
21. Bertuccio C, Veron D, Aggarwal PK, Holszman L, Tufo A: Vascular endothelial growth factor receptor 2 direct interaction with nephrin links VEGF-A signals to actin in kidney podocytes. J Biol Chem. 2011, 286:39933-44. 10.1074/jbc.M111.241620
22. Thomas SM, Brugge JS: Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 1997, 13:543-669. 10.1146/annurev.cellbio.13.1.543
23. Breccia M, Salaroli A, Molica M, Alimena G: Systematic review of dasatinib in chronic myeloid leukemia. Onco Targets Ther. 2015, 8:257-65. 10.2147/OTT.S53560
24. George B, Verma R, Soodi AA, et al.: Crk1/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease. J Clin Invest. 2012, 122:674-92. 10.1172/JCI60070
25. Iyoda M, Shibata T, Hirai Y, Kunin T, Akizawa T: Nitrosothiols attenuates renal injury and prolongs survival in chronic kidney disease. J Am Soc Nephrol. 2011, 22:1486-96. 10.1681/ASN.2010111158